Less Ads, More Data, More Tools Register for FREE

Sector movers: GSK leads defensive pharma stocks higher

Wed, 04th Feb 2015 14:35

A massive cash return by Glaxosmithkline gave the wider sector a lift on Wednesday, with defensive healthcare and pharmaceutical stocks also benefiting from a reduction in risk appetite as UK markets pulled back from a five-month high.Sales, profits and earnings slumped during the fourth quarter of the year at GSK due to headwinds in the US market, though the company pleased investors after confirming it would return £4bn cash from its deal with Novartis.The company also posted a dividend of 80p, a rise of 3%, and said it expected to maintain it at the same level in 2015.Glaxosmithkline's shares were up 1.1% at 1,468.5p.Meanwhile, healthcare outsourcer Synergy Health was also advancing 0.7% after saying it was on track to hit full-year forecasts as growth momentum picked up strongly in the third quarter.Sector giant Astrazeneca also gained, along with Hikma Pharmaceuticals, Consort Medical and Skyepharma, as defensive sectors such as pharmaceuticals rose amid a wider market decline.Pharma stocks have underperformed over the last few sessions as strong gains on the back of easing concerns over Greece pushed risk assets such as miners and oil producers higher. The FTSE 100 reached its highest close since early-September 2014 on Tuesday.Top performing sectors so far todayPharmaceuticals & Biotechnology 13,488.72 +1.14%Technology Hardware & Equipment 1,245.55 +1.11%Software & Computer Services 1,305.71 +0.41%Construction & Materials 4,637.12 +0.26%Electronic & Electrical Equipment 3,990.66 +0.25%Bottom performing sectors so far todayOil Equipment, Services & Distribution 16,336.00 -3.09%Industrial Metals & Mining 1,669.36 -2.81%Oil & Gas Producers 7,313.61 -2.02%Mining 14,227.96 -1.75%Food Producers & Processors 8,069.40 -1.56%

Related Shares

More News
Today 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Today 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with infla...

Today 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with pacl...

17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "impo...

17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Ba...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.